IO-108

PreclinicalBiologic

IImmune-Onc Therapeutics

IO-108 is one of 9 biologic programs targeting Advanced Liver Cancers. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Liver CancersActive, not recruiting

Advanced Liver CancersPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Advanced Liver Cancers

#DrugCompanyPhaseTrials

Avastin

Roche

Preclinical

1 2

Tecentriq

Roche

Preclinical

1 3

Actemra

CCelltrion

Preclinical

1 4

Tiragolumab

Roche

Preclinical

1 5

ADG126

Sanofi

Preclinical

1 6

Tobemstomig

Roche

Preclinical

1 7

TPST-1120

Roche

Preclinical

1 8

IO-108

IImmune-Onc Therapeutics

Preclinical

1 9

NKT2152

NNiKang Therapeutics, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalActive, not recruiting

Advanced Liver Cancers

NCT04524871

Clinical

Trials by Indication[1]

Solid Tumors1 trial

Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

Completed·IImmune-Onc Therapeutics·Phase 1·NCT05508100·38 enrolled

Patients With Advanced Solid Tumors1 trial

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Completed·IImmune-Onc Therapeutics·Phase 1·NCT05054348·91 enrolled

Advanced Liver Cancers1 trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Active, not recruiting· Roche logo

Roche·Preclinical·NCT04524871·518 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for IO-108. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IO-108 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IO-108. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Immune-Onc Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: IImmune-Onc Therapeutics

IO-108

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Solid Tumors1 trial

Patients With Advanced Solid Tumors1 trial

Advanced Liver Cancers1 trial

References

Drug Info

Quick Facts

Related News